ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OSTX vs SPRO // FREE CASH FLOW YIELD

OS Therapies Incorporated (NYSE) VS. Spero Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: OSTX 0 — SPRO 5
▲ FREE CASH FLOW YIELD LEADER: SPRO
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OSTX VS. SPRO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OSTX SPRO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 26.60% -61.60 SPRO /roic <GO>
EV/EBITDA & P/E Valuation — 5.1x — TIE /valuation <GO>
Free Cash Flow Yield ACTIVE -21.07% -19.53% -1.54 SPRO /fcf-yield <GO>
Operating Margin — 50.20% — TIE /operating-margins <GO>
Net Profit Margin — 68.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — 180.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 5/9 -4.00 SPRO /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 28.5 39.6 -11.10 SPRO /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 6.3x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $59.8M $60.6M -$778.0K SPRO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OSTX REV SPRO REV OSTX GROSS % SPRO GROSS % OSTX FCF SPRO FCF
FY 2025 $80.4M $12.6M — — -$14.2M -$12.6M
FY 2024 $19.1M $371.0K — — -$7.3M -$23.4M
FY 2023 $12.2M $933.0K — — -$3.0M -$33.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OSTX // BETA —
SPRO // BETA —